摘要
目的研究mdm2基因扩增与贲门癌的关系及其与各种临床病理因素之间的相关性。方法取新鲜贲门癌组织 ,用酚氯仿异物醇法提取基因组DNA ;用差异聚合酶链反应 (differentialpolymerasechainreaction ,dPCR)技术检测mdm2基因扩增。结果 38例贲门癌组织中 7例有mdm2基因扩增 (18.2 % ) ,高中分化组的mdm2基因扩增阳性率 (33 .3 % )较低分化组 (5 .0 % )高 (P <0 .0 5 ) ;而mdm2基因扩增与其它临床病理因素之间 ,如年龄、性别、组织类型和淋巴结转移等均无相关性 (P >0 .0 5 )。结论mdm2基因扩增在贲门癌并非少见 ,提示mdm2基因扩增可能是导致贲门癌野生型 p5 3功能丧失的重要遗传改变 ;
ObjectiveTo determine the prevalence and potential clinical value of mdm2 amplification in cardia gastric carcinoma.MethodsMdm2 amplification was examined by differential polymerase chain reaction (dPCR).ResultsMdm2 amplification was found in 7 of 38 cases ( 18.2 %). Otherwise, the positive rate of mdm2 gene amplification in higher grade group was higher than that in the lower grade group ( 33.3 % vs 5%), and the difference was significant (P< 0.05 ). There was no correlation observed between the alteration and other clinicopathological parameters, such as sex, age, histological subtype, lymph node metastasis,et al. ConclusionThe data suggest that mdm2 amplification might play an important role in cardia gastric carcinoma. It maybe a mechanism for cells to escape from the regulatory pathway of p53. The detection of the alteration may be helpful to assess the prognosis of cardia gastric carcinoma.
出处
《河北医科大学学报》
CAS
2001年第1期1-4,共4页
Journal of Hebei Medical University